How does Revumenib work inside my body to fight leukemia?
Revumenib blocks a protein called menin that helps leukemia cells survive and multiply. By turning off menin, Revumenib starves cancer cells and lets your immune system destroy them. AUGMENT-101 showed 52% of patients achieved complete remission (no cancer cells in blood or bone marrow) [1].
Revumenib is an oral menin inhibitor—a small molecule that fits into menin like a key in a lock and shuts it down [2]. In the AUGMENT-101 trial, 111 patients with KMT2A-rearranged leukemia took 110 mg once daily, and 58 (52%) achieved complete remission within 4–6 weeks [1]. The drug works only if your leukemia has a KMT2A rearrangement or NPM1 mutation—your oncologist must test your cancer cells first [2].
Inside your leukemia cells, menin normally partners with a protein called KMT2A (or NPM1) to turn on genes that make cancer cells grow and resist chemotherapy [2]. When Revumenib blocks menin, this partnership breaks apart, and the cancer-growth genes stay silent [4]. Your bone marrow then produces normal blood cells again, and your immune system can recognize and kill the remaining leukemia cells [1].
Most patients start at 110 mg once daily and take it by mouth with food to reduce nausea [7]. If you tolerate it well after 2–4 weeks, your oncologist may increase the dose to 160 mg daily for stronger effect [7]. Response usually happens within 4–6 weeks; if no improvement by week 8, your doctor may switch to a combination regimen (Revumenib + azacitidine + venetoclax) [5][6].
Ask your oncologist: 'Has my leukemia been tested for KMT2A or NPM1 mutations? If yes, what percentage of my cancer cells carry the mutation?' This tells you how likely Revumenib is to work for you [1].